Emergent BioSolutions Inc. (EBS) said that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application or sBLA for the expansion of the indication for ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection.The vaccine was first approved by the FDA in 2007 for active immunization for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection.

Emergent BioSolutions Inc.（EBS）表示，美国食品和药物管理局已批准补充生物制剂许可证申请或sBLA，以扩大ACAM2000（天花和Mpox（痘苗）疫苗，活疫苗）的适应症，包括预防Mpox感染高危人群的Mpox疾病。该疫苗于2007年首次被FDA批准用于主动免疫，以预防被确定为天花感染高危人群的天花疾病。

Mpox, previously called monkeypox, is an infectious disease endemic to central and west Africa caused by the double-stranded DNA mpox virus. The virus is a member of the Orthopoxvirus genus in the Poxviridae family, related to the virus which caused smallpox.ACAM2000 is indicated in the U.S. for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox and mpox infection..

。该病毒是痘病毒科正痘病毒属的成员，与引起天花的病毒有关。ACAM2000在美国用于主动免疫，以预防天花和mpox感染高危人群的天花和mpox疾病。。

EBS closed Thursday's regular trading at $8.91. In the after-hours trading, the stock gained $1.39 or 15.60%.For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News

EBS周四的常规交易收于8.91美元。在盘后交易中，该股上涨1.39美元，涨幅15.60%。有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻